USFDA scrutiny on Indian plants is rising but pharma is more prepared than a decade ago

Upgrades and de-risking are set to blunt bad findings

USFDA inspections in India have accelerated recently, raising concerns about potential adverse observations. But industry insiders say today’s pharma firms are better positioned than a decade ago, thanks to tech upgrades and de-risking strategies. Analysts expect limited impact on earnings and stock prices, as companies can better cushion regulatory actions.